{"success":true,"data":{"pressRelease":{"id":"154732","rtpr_id":"nGNXbqNsRG-20260929","ticker":"NOVOB","exchange":"Nasdaq Copenhagen","all_tickers":["NOVOB"],"title":"Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596","author":"Globe Newswire","published_at":"2026-09-29T04:35:11.289Z","article_body":"* HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly\noral dosing            \n* Total potential deal value is up to 2.6 billion US dollars, including 300\nmillion dollars upfront, as well as potential sales royalties\nBagsværd, Denmark, 29 September 2026 – Novo Nordisk today announced that it\nhas entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK)\nfor HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and\ngastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential\nfor once-weekly oral dosing.\n\nUnder the terms of the agreement, Novo will obtain exclusive rights to\ndevelop, manufacture and commercialise HRS-1596 globally, excluding mainland\nChina, Hong Kong, Macao and Taiwan. The potential total value of the agreement\nis up to 2.6 billion US dollars contingent on the achievement of applicable\ndevelopment, regulatory and commercial milestones. This includes a 300 million\ndollars upfront payment. In addition, Hengrui Pharma is eligible to receive\nroyalties based on net sales of HRS-1596 within the licensed territory.\n\n\"Novo has pioneered the field of oral peptides and as leaders, we continuously\nlook to advance our broad and deep oral pipeline across obesity, diabetes and\nother cardiometabolic diseases through our strong internal capabilities and\nleading external innovation,\" said Martin Holst Lange, executive vice\npresident, Research & Development and chief scientific officer at Novo.\n\"Hengrui Pharma has a proven track record of discovering and advancing\ninnovative therapies with the patients in the center, and we are excited to\nadd HRS-1596 to our growing pipeline and to explore its potential to raise the\nbar for convenience in the field.\"\n\n“We are committed to continuous innovation, bringing better treatments to\npatients. HRS-1596 reflects this commitment in metabolic diseases, with the\npotential to offer the convenience of once-weekly oral administration,” said\nFrank Jiang, MD, Ph.D., Executive Vice President and Chief Strategy Officer of\nHengrui Pharma. “This collaboration brings together Hengrui’s innovation\nstrengths and Novo’s global leadership in GLP-1 therapies and obesity care.\nTogether, we aim to advance this innovative therapy for patients worldwide.”\n\nHRS-1596 is designed to reduce weight and improve glycemic control through\nmultiple mechanisms, including appetite suppression, stimulation of insulin\nsecretion, and improved insulin sensitivity, supporting its potential use in\nobesity, type 2 diabetes, and other metabolic diseases. HRS-1596 has potential\nto be developed for once-weekly oral administration, which would substantially\nreduce dosing frequency and improve convenience compared with current\nofferings. Hengrui Pharma has received approval in China to initiate phase 1\nclinical trials with HRS-1596 for weight management and type 2 diabetes.\n\nThe license agreement is subject to clearance under the U.S. Hart-Scott-Rodino\nAntitrust Improvements Act and the satisfaction of other customary closing\nconditions. The transaction is expected to close in the fourth quarter of\n2026.\n\nAbout Hengrui Pharma \nHengrui Pharma is an innovative, global pharmaceutical company dedicated to\nthe research, development and commercialization of high-quality medicines to\naddress unmet clinical needs. Its therapeutic areas of focus include oncology,\nmetabolic and cardiovascular diseases, immunological and respiratory diseases,\nand neuroscience. Driven by a patient-focused philosophy since its founding in\n1970, Hengrui Pharma remains committed to advancing human health by striving\nto conquer diseases, improve health, and extend lives through the power of\nscience and technology. For more information, visit us at Hengrui.com and\nfollow us on LinkedIn.\n\nAbout Novo\nNovo is the global healthcare company that believes lasting health starts now.\nFor over a century, we’ve combined leading scientific expertise with a deep\nunderstanding of people’s lives. We develop treatments and support that help\nmillions of people make progress they can see, feel and sustain now and in the\nfuture. Every day, over 67,000 employees around the world advance our purpose\nto drive change for lasting health. Through our partnerships, programmes and\ninvestments, we’re working to prevent disease, expand access to treatments\nand reduce our environmental impact to help even more people live healthier\nlives. For more information, visit novonordisk.com\n(https://www.globenewswire.com/Tracker?data=OATJzeA-j2PqXrYLtNrWDBAuJpeK92qQEYAeLvSDJc_WacFunijDsEckueVtpj9ZfjZ2I5HRCfZXqOv4cX7jZIYUxmNLEvZlnWxkQ_gUyhk=)\nand follow us on Instagram\n(https://www.globenewswire.com/Tracker?data=vFhxhQT88aGznCYAKMmLvY1_rV5YvlL8z3Nf69CrcDVLXM_sKhEuCzTPb1V-UwzoZgGlI65hq4m41Ai2KzmahLP-BpHMDkPFRjhiRs0T0Gk=),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=D-yJbQxv3wtLkxbhump6uVWFgXSK2kKpsqrGvUL88dx2iCkdABiTOhU83gPlr_jlKC_6RlDklXTaED-Z_9zecMvCnBgwLKmkaj-S6tSdBaXyp3quCohkX4FEJHjpG-7N),\nTikTok\n(https://www.globenewswire.com/Tracker?data=AeXXoI_uQX1mg5AL4WtdoavMy0auZCia3Q_fdoLUYpQJYJb7koj70qPEKwpSwrK0mE1CSWcH00_IaU2l7cWm6HnkgEQGik6VwgR5svEsx04=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=sOXMzG46zaPFc3ckQXNTBiZE8ZYXmluVv7R52grKytPRNrZENXQ1GIQkTzpREf-6YcTIzLHd_U1gQY5vVqMt1EeQyn2idIywRevkcBBokwc=),\nX\n(https://www.globenewswire.com/Tracker?data=bEXsU7NVHyP9hLj4kVr3hbtAl22GKw7dHQyjcD5KOIcUoDKDAjYQNQONpBHyciOHk_3594EsHIFi0FkRgKPieg==)\nand YouTube\n(https://www.globenewswire.com/Tracker?data=dQWjjzvsB9XHSE9X9Azb3Q-FGJhC8FlA6PIu3hOOkSFoYCdQi04Aw5TiJ5cSJTwOKCMjnvlGu1YFF8uY_CRxU-Hzj12rPmuBv1fWcC1GPWk=). \n\nContacts for further information\n\n Novo Media:                                                                                                                              \n Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com          Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com  \n Novo Investors:                                                                                                                          \n Michael Novod +45 3075 6050 nvno@novonordisk.com                     Sina Meyer +45 3079 6656 azey@novonordisk.com                       \n Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com  Max Ung +45 3077 6414 mxun@novonordisk.com                          \n Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com                Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com                \n Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com     Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com                \n\n\n\nAttachment\n*     PR260929-Hengrui\n(https://ml-eu.globenewswire.com/Resource/Download/ebc4cc3d-0ce4-429c-aa17-b2e3da57ac4a)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f87e6f85-3e50-4571-b9e5-8f683431f855)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbqNsRG-20260929","title":"Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596","author":"Globe Newswire","ticker":"NOVOB","created":"2026-09-29T04:35:11.289Z","tickers":["NOVOB"],"exchange":"Nasdaq Copenhagen","article_body":"* HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly\noral dosing            \n* Total potential deal value is up to 2.6 billion US dollars, including 300\nmillion dollars upfront, as well as potential sales royalties\nBagsværd, Denmark, 29 September 2026 – Novo Nordisk today announced that it\nhas entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK)\nfor HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and\ngastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential\nfor once-weekly oral dosing.\n\nUnder the terms of the agreement, Novo will obtain exclusive rights to\ndevelop, manufacture and commercialise HRS-1596 globally, excluding mainland\nChina, Hong Kong, Macao and Taiwan. The potential total value of the agreement\nis up to 2.6 billion US dollars contingent on the achievement of applicable\ndevelopment, regulatory and commercial milestones. This includes a 300 million\ndollars upfront payment. In addition, Hengrui Pharma is eligible to receive\nroyalties based on net sales of HRS-1596 within the licensed territory.\n\n\"Novo has pioneered the field of oral peptides and as leaders, we continuously\nlook to advance our broad and deep oral pipeline across obesity, diabetes and\nother cardiometabolic diseases through our strong internal capabilities and\nleading external innovation,\" said Martin Holst Lange, executive vice\npresident, Research & Development and chief scientific officer at Novo.\n\"Hengrui Pharma has a proven track record of discovering and advancing\ninnovative therapies with the patients in the center, and we are excited to\nadd HRS-1596 to our growing pipeline and to explore its potential to raise the\nbar for convenience in the field.\"\n\n“We are committed to continuous innovation, bringing better treatments to\npatients. HRS-1596 reflects this commitment in metabolic diseases, with the\npotential to offer the convenience of once-weekly oral administration,” said\nFrank Jiang, MD, Ph.D., Executive Vice President and Chief Strategy Officer of\nHengrui Pharma. “This collaboration brings together Hengrui’s innovation\nstrengths and Novo’s global leadership in GLP-1 therapies and obesity care.\nTogether, we aim to advance this innovative therapy for patients worldwide.”\n\nHRS-1596 is designed to reduce weight and improve glycemic control through\nmultiple mechanisms, including appetite suppression, stimulation of insulin\nsecretion, and improved insulin sensitivity, supporting its potential use in\nobesity, type 2 diabetes, and other metabolic diseases. HRS-1596 has potential\nto be developed for once-weekly oral administration, which would substantially\nreduce dosing frequency and improve convenience compared with current\nofferings. Hengrui Pharma has received approval in China to initiate phase 1\nclinical trials with HRS-1596 for weight management and type 2 diabetes.\n\nThe license agreement is subject to clearance under the U.S. Hart-Scott-Rodino\nAntitrust Improvements Act and the satisfaction of other customary closing\nconditions. The transaction is expected to close in the fourth quarter of\n2026.\n\nAbout Hengrui Pharma \nHengrui Pharma is an innovative, global pharmaceutical company dedicated to\nthe research, development and commercialization of high-quality medicines to\naddress unmet clinical needs. Its therapeutic areas of focus include oncology,\nmetabolic and cardiovascular diseases, immunological and respiratory diseases,\nand neuroscience. Driven by a patient-focused philosophy since its founding in\n1970, Hengrui Pharma remains committed to advancing human health by striving\nto conquer diseases, improve health, and extend lives through the power of\nscience and technology. For more information, visit us at Hengrui.com and\nfollow us on LinkedIn.\n\nAbout Novo\nNovo is the global healthcare company that believes lasting health starts now.\nFor over a century, we’ve combined leading scientific expertise with a deep\nunderstanding of people’s lives. We develop treatments and support that help\nmillions of people make progress they can see, feel and sustain now and in the\nfuture. Every day, over 67,000 employees around the world advance our purpose\nto drive change for lasting health. Through our partnerships, programmes and\ninvestments, we’re working to prevent disease, expand access to treatments\nand reduce our environmental impact to help even more people live healthier\nlives. For more information, visit novonordisk.com\n(https://www.globenewswire.com/Tracker?data=OATJzeA-j2PqXrYLtNrWDBAuJpeK92qQEYAeLvSDJc_WacFunijDsEckueVtpj9ZfjZ2I5HRCfZXqOv4cX7jZIYUxmNLEvZlnWxkQ_gUyhk=)\nand follow us on Instagram\n(https://www.globenewswire.com/Tracker?data=vFhxhQT88aGznCYAKMmLvY1_rV5YvlL8z3Nf69CrcDVLXM_sKhEuCzTPb1V-UwzoZgGlI65hq4m41Ai2KzmahLP-BpHMDkPFRjhiRs0T0Gk=),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=D-yJbQxv3wtLkxbhump6uVWFgXSK2kKpsqrGvUL88dx2iCkdABiTOhU83gPlr_jlKC_6RlDklXTaED-Z_9zecMvCnBgwLKmkaj-S6tSdBaXyp3quCohkX4FEJHjpG-7N),\nTikTok\n(https://www.globenewswire.com/Tracker?data=AeXXoI_uQX1mg5AL4WtdoavMy0auZCia3Q_fdoLUYpQJYJb7koj70qPEKwpSwrK0mE1CSWcH00_IaU2l7cWm6HnkgEQGik6VwgR5svEsx04=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=sOXMzG46zaPFc3ckQXNTBiZE8ZYXmluVv7R52grKytPRNrZENXQ1GIQkTzpREf-6YcTIzLHd_U1gQY5vVqMt1EeQyn2idIywRevkcBBokwc=),\nX\n(https://www.globenewswire.com/Tracker?data=bEXsU7NVHyP9hLj4kVr3hbtAl22GKw7dHQyjcD5KOIcUoDKDAjYQNQONpBHyciOHk_3594EsHIFi0FkRgKPieg==)\nand YouTube\n(https://www.globenewswire.com/Tracker?data=dQWjjzvsB9XHSE9X9Azb3Q-FGJhC8FlA6PIu3hOOkSFoYCdQi04Aw5TiJ5cSJTwOKCMjnvlGu1YFF8uY_CRxU-Hzj12rPmuBv1fWcC1GPWk=). \n\nContacts for further information\n\n Novo Media:                                                                                                                              \n Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com          Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com  \n Novo Investors:                                                                                                                          \n Michael Novod +45 3075 6050 nvno@novonordisk.com                     Sina Meyer +45 3079 6656 azey@novonordisk.com                       \n Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com  Max Ung +45 3077 6414 mxun@novonordisk.com                          \n Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com                Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com                \n Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com     Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com                \n\n\n\nAttachment\n*     PR260929-Hengrui\n(https://ml-eu.globenewswire.com/Resource/Download/ebc4cc3d-0ce4-429c-aa17-b2e3da57ac4a)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f87e6f85-3e50-4571-b9e5-8f683431f855)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-29T04:35:11.330147726Z","server_sent_at_ms":1790656511330},"received_at":"2026-09-29T04:35:11.400Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}